Search

Reactive oxygen species (ROS), a byproduct of cellular metabolism, damage intracellular macromolecules and, when present in excess, can promote normal hematopoietic stem cell differentiation and exhaustion (1-3). However, mechanisms that regulate the amount of ROS in leukemia-initiating cells (LICs) and the biological role of ROS in these cells are largely unknown. We show here that the [ROS.sup.low] subset of [CD44.sup.+] cells in T cell acute lymphoblastic leukemia (T-ALL), a malignancy of immature T cell progenitors, is highly enriched in the most aggressive LICs and that ROS accumulation is restrained by downregulation of protein kinase Cθ (PKC-θ). Notably, primary mouse T-ALLs lacking PKC-θ show improved LIC activity, whereas enforced PKC-u expression in both mouse and human primary T-ALLs compromised LIC activity. We also show that PKC-θ is regulated by a new pathway in which NOTCH1 induces runt-related transcription factor 3 (RUNX3), RUNX3 represses RUNX1 and RUNX1 induces PKC-θ. NOTCH1, which is frequently activated by mutation in T-ALL (4-6) and required for LIC activity in both mouse and human models (7), (8) thus acts to repress PKC-θ. These results reveal key functional roles for PKC-θ and ROS in T-ALL and suggest that aggressive biological behavior in vivo could be limited by therapeutic strategies that promote PKC-θexpression or activity, or the accumulation of ROS., Current therapies for T-ALL are curative in 80% of pediatric cases, but only 40% of adults with T-ALL survive beyond 5 years (9). The ineffectiveness of chemotherapeutic regimens in both [...]

We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathologic microenvironment of cancer and fibrotic disease. Our analysis of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-associated stroma and limited expression in healthy tissues. Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models. Inhibition of LOXL2 resulted in a marked reduction in activated fibroblasts, desmoplasia and endothelial cells, decreased production of growth factors and cytokines and decreased transforming growth factor-β (TGF-β) pathway signaling. AB0023 outperformed the small-molecule lysyl oxidase inhibitor β-aminoproprionitrile. The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncologic and fibrotic diseases., Extensive clinical evidence and mouse models of tumorigenesis support the crucial role of the microenvironment in promoting tumor growth and metastasis (1-7). Tumor-associated fibroblasts constitute the major cell type of [...]

A preliminary test was conducted, where the effects of [gamma]-secretase blockade on c-myc mRNA levels was analyzed in five human T-cell lymphoblastic leukemias and lymphomas (T-ALL) cell lines, that require Notch signals for growth and was further encouraged with experiments, using c-myc-dependent murine T-ALL cells. The data showed that implicate c-myc is a developmentally regulated direct downstream target of Notch1, which contributes to the growth of T-ALL cells.